Top Medical Stocks To Own For 2018

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry

Merck’s Keytruda Achieves Success In Phase 3 Study As A Combo Therapy

News: On Tuesday, Merck (MRK) announced positive results in a phase 3 study, using a combination of Keytruda and Alimta, treating patients with previously untreated non-small cell lung cancer (NSCLC). Alimta is a lung cancer drug developed by Eli Lilly (LLY). The phase 3 study, named Keynote-189, met on both endpoints of the study. The combo improved progression-free survival and overall-survival in patients.

Analysis: This news is really good for Merck. Not only did it report positive results for this indication, but it did so very early. That’s because this was just an interim look at the data. The final data for this trial was not expected until early 2019. The news might get even better, because this was just top-line results that were reported. The full set of detailed data from this study won’t be revealed until an upcoming medical conference. That means that investors have a lot to look forward too. This also trumps the notion that a Keytruda- chemo combo won’t work for first-line lung cancer. That’s because Merck pulled its European application last year for a Keytruda-chemo combo, because of results from a small phase 2 study. At that time, everyone was placing bets that the phase 3 study would also not show impressive data. Well, as you can see Merck has proved everyone wrong, and now it has a lot to hang its hat on. This win for Merck is bad for both Roche (OTCQX:RHHBY) and Bristol-Myers Squibb (BMY) which is why both traded lower as soon as the Merck results were announced.

Top Medical Stocks To Own For 2018: Sears Holdings Corporation(SHLD)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Just in the past few weeks, Wall Street has seen bankruptcy filings from sporting goods retailer Gander Mountain, RadioShack successor General Wireless Operations, everyday value price department store operator Gordmans Stores (GMAN) and appliances, electronics and furniture retailer HHGregg (HGG) . Last Wednesday, children’s apparel retailer Gymboree cautioned it was running low on cash and may not survive. Sears Holdings Corp. (SHLD) voiced concerns on Tuesday about its ability to stay in business, while women’s apparel chain Bebe (BEBE) is reportedly on the brink of closing all 170 of its stores.

  • [By Ashley Moore]

    The deal, which was announced on July 20, will allow Sears Holdings Corp.’s (Nasdaq: SHLD) Kenmore home appliance brand to be sold on Amazon. This is the first official time the online retailer has had access to the Sears-exclusive brand. (Some Kenmore appliances were previously sold on Amazon through third-party sellers.)

  • [By Douglas A. McIntyre]

    The CEO of Sears Holdings Corp. (NYSE: SHLD) will try to use his hedge fund to buy some of the failing retailer’s assets. According to The Wall Street Journal:

  • [By Paul Ausick]

    Sears Holdings Corp. (NASDAQ: SHLD).Between Sears and Kmart stores, the company plans 142 store closings, with more likely.

    Sports Authority.Another bankruptcy, with 140 stores closing.

  • [By WWW.THESTREET.COM]

    Wall Street may want to temper their exuberance over the quarter struggling Sears Holdings Corp. (SHLD) just announced. 

    “Sears’ declining cash balance heightens its need to continue to source $2 billion of liquidity annually,” David Silverman, Senior Director, U.S. Corporates at Fitch Ratings told TheStreet via email. “The company’s ability to continue to operate is dependent on their ability to continue finding these sources — it currently has a number of unencumbered store locations which could be monetized.”

  • [By Ashley Moore]

    Lewitt first warned investors that Sears Holding Corp. (Nasdaq: SHLD) was headed for disaster in December 2014. Since then, it has dropped more than 63%, netting investors huge gains if they followed his advice to short this stock.

Top Medical Stocks To Own For 2018: BorgWarner Inc.(BWA)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    General Motors Company (NYSE: GM) is projected to report quarterly earnings at $1.24 per share on revenue of $34.66 billion.
    Bristol-Myers Squibb Company (NYSE: BMY) is estimated to report quarterly earnings at $0.85 per share on revenue of $5.24 billion.
    United Parcel Service, Inc. (NYSE: UPS) is expected to report quarterly earnings at $1.55 per share on revenue of $16.44 billion.
    Time Warner Inc. (NYSE: TWX) is projected to report quarterly earnings at $1.74 per share on revenue of $7.91 billion.
    ConocoPhillips (NYSE: COP) is expected to report quarterly earnings at $0.74 per share on revenue of $8.81 billion.
    PepsiCo, Inc. (NYSE: PEP) is expected to report quarterly earnings at $0.93 per share on revenue of $12.4 billion.
    American Airlines Group Inc. (NASDAQ: AAL) is estimated to report quarterly earnings at $0.72 per share on revenue of $10.42 billion.
    Southwest Airlines Co (NYSE: LUV) is expected to report quarterly earnings at $0.74 per share on revenue of $5.01 billion.
    Fiat Chrysler Automobiles N.V. (NYSE: FCAU) is estimated to report quarterly earnings at $0.8 per share on revenue of $34.52 billion.
    Union Pacific Corporation (NYSE: UNP) is projected to report quarterly earnings at $1.66 per share on revenue of $5.38 billion.
    D.R. Horton, Inc. (NYSE: DHI) is expected to report quarterly earnings at $0.85 per share on revenue of $3.76 billion.
    The Hershey Company (NYSE: HSY) is estimated to report quarterly earnings at $1.4 per share on revenue of $1.94 billion.
    Praxair, Inc. (NYSE: PX) is expected to report quarterly earnings at $1.56 per share on revenue of $2.94 billion.
    Altria Group, Inc. (NYSE: MO) is projected to report quarterly earnings at $0.92 per share on revenue of $4.63 billion.
    Shire plc (NASDAQ: SHPG) is estimated to report quarterly earnings at $3.54 per share on revenue of $3.72 billion.
    Oshkosh Corporation (NYSE: OSK) is projected to report quarter
  • [By Ben Levisohn]

    Yesterday, Morgan Stanleys Adam Jonas cut Delphi Automotive (DLPH) to Underweight from Overweight citing the threat posed by electric cars (and not just Tesla Motors (TSLA)). Today, Bairds David Leiker and team offer a fuller defense of Delphi Automotive, as well as Borg Warner (BWA) and Lear (LEA):

  • [By Ben Levisohn]

    Yesterday, I dubbed the selloff in auto stocks “car-pocalypse now,” as shares of everything car related tumbled following disappointing auto sales. Shares of General Motors (GM) and Ford Motor (F)? Check. Auto-part makers like BorgWarner (BWA)? Check. Used-car sellers like AutoNation (AN) and CarMax (KMX)? Check. Auto-part retailers like O’Reilly Automotive (ORLY) and AutoZone (AZO)? Oh yeah. So is it time to panic?

Top Medical Stocks To Own For 2018: WSFS Financial Corporation(WSFS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “WSFS Financial (WSFS) to Release Quarterly Earnings on Monday” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3364455/wsfs-financial-wsfs-to-release-quarterly-earnings-on-monday.html.

Top Medical Stocks To Own For 2018: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By ]

    Nu Skin Enterprises (NYSE: NUS) is benefiting from two key trends: its strong presence in Asia where it books 79% of its revenue and leading brand awareness with millennials. The company has increased its dividend every year since 2001, now paying a 2% yield, and maintains a share repurchase program that returns excess cash to shareholders.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

Top Medical Stocks To Own For 2018: Adeptus Health Inc.(ADPT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Adeptus Health Inc (NASDAQ: ADPT) shares dropped 66 percent to $9.09 after the company posted downbeat quarterly results and lowered its FY16 EBITDA outlook.

  • [By Lisa Levin]

    Shares of Adeptus Health Inc (NYSE: ADPT) were down around 30 percent to $1.30. Medical Properties Trust disclosed that it has agreed in principle with Deerfield Management to restructuring in bankruptcy to Adeptus Health.

Top Medical Stocks To Own For 2018: KongZhong Corporation(KZ)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20: